Atossa Therapeutics Announces Participation in Virtual Summit
Atossa Therapeutics to Join the 2024 Maxim Healthcare Summit
SEATTLE — Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company committed to developing innovative solutions in oncology, has exciting news to share. The company has announced that Michael Parks, the Vice President of Investor and Public Relations, will take part in a virtual fireside chat during the 2024 Maxim Healthcare Virtual Summit.
Event Details and Participation
This engaging session is scheduled for Wednesday, October 16, 2024, at 12:00 p.m. EDT. Through this platform, Atossa aims to connect with a wider audience interested in their pioneering efforts in the field of cancer treatment, particularly focusing on breast cancer.
Innovative Developments in Oncology
Atossa Therapeutics has dedicated its resources to addressing significant unmet medical needs within oncology. Their research is centered around (Z)-endoxifen, which is being explored for its potential to prevent and treat breast cancer. This innovative approach reflects Atossa's commitment to enhancing patient care and advancing treatment options.
Accessing the Live Webcast
For those eager to learn more, the live webcast for the event will be accessible to interested parties. Registration for the conference will provide the chance to gain insights directly from Atossa’s leadership on their current projects and future aspirations within the biopharmaceutical industry.
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is at the forefront of developing transformative treatments for cancer patients. Their focus on breast cancer positions them uniquely in the market, as they leverage groundbreaking research to potentially revolutionize treatment protocols. The company is devoted to refining their product pipeline to provide effective and innovative cancer therapies.
Contact Information
If you wish to learn more about Atossa Therapeutics or have specific inquiries, Michael Parks, the Vice President of Investor and Public Relations, is available for contact. He can provide additional information about the company’s initiatives and its impact on oncology research.
Contact:
Michael Parks
Vice President, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
Frequently Asked Questions
What is Atossa Therapeutics focusing on in their research?
Atossa Therapeutics is primarily focused on developing treatments for breast cancer using (Z)-endoxifen.
When will the virtual summit take place?
The 2024 Maxim Healthcare Virtual Summit will occur on October 16, 2024, at 12:00 p.m. EDT.
Who is representing Atossa at the summit?
Michael Parks, the Vice President of Investor and Public Relations, will represent Atossa Therapeutics at the summit.
How can I access the virtual summit?
Interested individuals can register for the event to access the live webcast via the conference website.
What is Atossa's commitment in the pharmaceutical industry?
Atossa is dedicated to addressing unmet medical needs in oncology, focusing on innovative solutions for cancer treatment.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Invisalign Palatal Expander System Launched in Singapore
- Transforming Orthodontics: Invisalign Palatal Expander Launch
- Industrial Enzymes Market Growth Driven by AI and Food Demands
- Ruth's Chris Reopens, Celebrating Community Strength and Resilience
- Emerging Trends in the Two-Wheeler Catalytic Converter Market
- Global Shrimp Market Trends and Innovations for 2024-2028
- Emerging Trends Fueling Growth in the Window Films Market
- Tokyo Metro's IPO Pricing Marks Major Milestone for Japan
- US Stock Futures Remain Stable as Earnings Season Approaches
- Transforming the US Home Furniture Market: Growth Powered by AI
Recent Articles
- Understanding the Class Action Against Elanco Animal Health
- Arm Holdings Sees Stock Surge Amid AI and Mobile Tech Demand
- Data Breach Investigation and What Gryphon Customers Should Know
- Investors Unite: The Class Action Against Edwards Lifesciences
- Investigation Launched After Data Breach at Tri-City Healthcare
- Oklo Inc Capitalizes on Google Nuclear Energy Initiative
- Unveiling AECOM's Ten-Year Growth Journey for Investors
- Athena Technology II Receives Audit Opinion Raising Concerns
- Investing in Wingstop: A Journey Over the Last Five Years
- Understanding Bank of America's Upcoming Earnings Report Insights
- Natus Displays Innovative Neuromonitoring at NCS Conference
- Helen Masters Takes Charge at Smartsheet for APJ Growth
- Bel Fuse Appoints Uma Pingali as Global Head of Sales Strategy
- Helius Medical Technologies Fights for Fair PoNS Device Reimbursement
- Evercore's Predictions for TAP, EXPE, and ABNB Ahead of Earnings
- Innovations in Compounding: Jennifer Lines to Inspire at Seminar
- Helius Medical Technologies Updates on PoNS Device Reimbursement
- Bel Fuse Inc. Welcomes Uma Pingali as Global Sales Leader
- Atossa Therapeutics Announces Participation in 2024 Healthcare Summit
- Helen Masters Takes Leadership Role at Smartsheet in APJ Region
- Understanding the Ongoing Class Action Against Iris Energy Limited
- Top Wealth Group Holding Limited Successfully Completes $10.8M Offering
- Bitcoin Cash Surges as Cryptocurrency ETFs Attract Investors
- Seeking Justice: United Parcel Service Investors Class Action
- A Fresh Look at the Upcoming Growth in Alcoholic Beverages Market
- EnLink Midstream Announces Third Quarter Distribution Update
- A Comprehensive Look at the Growing Condiments Market
- Growth Surge in Ophthalmology Devices Market Due to AI Innovations and Demand
- Stephens Initiates Valvoline Coverage with Optimistic Outlook
- Moderna Faces Tough Times with Price Target Reduced to $55
- Market Reactions to Recent Developments in Key Stocks
- Top Wealth Group Secures $10.8 Million Through Share Offering
- GEICO Sets Up Inspection Sites in Florida After Hurricane
- Exploring the Dynamics of Roku's Options Trading Landscape
- Onto Innovation's Upcoming Q3 2024 Financial Results Overview
- Understanding MARA Holdings' Growing Options Market Trends
- Stewart Information Services to Discuss Q3 2024 Results Soon
- Investor Insights: Unpacking the Swan Song for HLT Options
- United Airlines Prepares for Q3 with New Routes and Challenges
- Goldman Sachs Predicts Stock Boost with Trump Victory
- CBL Properties Declares Significant Dividend and Expansion Plans
- DCG ONE Enhances Marketing Services with Cirangle Design Buyout
- Sanjiv Razdan Takes the Helm as CEO of The Joint Corp.
- PTC Therapeutics Advances with New Drug Application for PKU Drug
- Phillips 66 Divests Key Stake as Part of Strategic Restructuring
- Modine Manufacturing's New CIO Sets Strategic Digital Vision
- Winnebago's Strategic Shift: Leadership in Towable RVs
- Coty Inc. Sees Steady Growth Despite Market Challenges Ahead
- Leadership Changes in AI: Microsoft VP Moves to OpenAI
- Brazilian Stock Market Gains Strong Momentum Amid Diverse Sectors